WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
V03AB54pralidoxime and atropine01.02.20232024
S01XA31pegcetacoplan01.02.20232024
S01CA12loteprednol and antiinfectives01.02.20232024
S01BA16difluprednate01.02.20232024
S01AX24polihexanide01.02.20232024
S01AA32bacitracin01.02.20232024
P02BA03arpraziquantel01.02.20232024
N07XX21eplontersen01.02.20232024
N07XX19sodium phenylbutyrate and ursodoxicoltaurine01.02.20232024
N06DX04lecanemab01.02.20232024
N05CJ03daridorexant01.02.20232024
N02CC51sumatriptan and naproxen01.02.20232024
N02BA67magnesium salicylate, combinations excl. psycholeptics01.02.20232024
N02AJ23hydrocodone and ibuprofen01.02.20232024
N02AJ22hydrocodone and paracetamol01.02.20232024
N02AD51pentazocine and naloxone01.02.20232024
M09AX14givinostat01.02.20232024
M04AC51colchicine and probenecid01.02.20232024
M01AE57naproxen and diphenhydramine01.02.20232024
L04AJ06zilucoplan01.02.20232024
L04AG15divozilimab01.02.20232024
L04AF08ritlecitinib01.02.20232024
L04AC25levilimab01.02.20232024
L04AC24mirikizumab01.02.20232024
L03AX22leniolisib01.02.20232024
L03AB17sampeginterferon beta-1a01.02.20232024
L02BX53abiraterone and prednisolone01.02.20232024
L02BA04elacestrant01.02.20232024
L01XL09tabelecleucel01.02.20232024
L01XL08lisocabtagene maraleucel01.02.20232024
L01XK52niraparib and abiraterone01.02.20232024
L01FX25mosunetuzumab01.02.20232024
L01FX24teclistamab01.02.20232024
L01FF12serplulimab01.02.20232024
L01FF11sugemalimab01.02.20232024
L01EL05pirtobrutinib01.02.20232024
L01EL04orelabrutinib01.02.20232024
L01EK04fruquintinib01.02.20232024
L01EJ04momelotinib01.02.20232024
L01BC58decitabine, combinations01.02.20232024
J07BX05respiratory syncytial virus vaccines01.02.20232024
J07BN05covid-19, virus-like particles01.02.20232024
J01DE51cefepime and beta-lactamase inhibitor01.02.20232024
J01DC52cefuroxime and beta-lactamase inhibitor01.02.20232024
G04BX17sodium salicylate and methenamine01.02.20232024
G04BD15vibegron01.02.20232024
D05AX07tapinarof01.02.20232024
D05AX06roflumilast01.02.20232024
C10BX20rosuvastatin and telmisartan01.02.20232024
C09BX06perindopril, bisoprolol, amlodipine and indapamide01.02.20232024
C05XX01beperminogene perplasmid01.02.20232024
C05AX06phenylephrine01.02.20232024
C01CX10omecamtiv mecarbil01.02.20232024
C01CA28centhaquine01.02.20232024
B06AX05exagamglogene autotemcel01.02.20232024
B02BX10concizumab01.02.20232024
B02BD15valoctocogene roxaparvovec01.02.20232024
B01AF51rivaroxaban and acetylsalicylic acid01.02.20232024
A16AX23leriglitazone01.02.20232024
A16AB27pabinafusp alfa01.02.20232024
A16AB26eladocagene exuparvovec01.02.20232024
A10BD29sitagliptin and dapagliflozin01.02.20232024
A10BD28metformin and teneligliptin01.02.20232024
A10AE07insulin icodec01.02.20232024
A07FA03escherichia coli01.02.20232024
A05AA05ursodoxicoltaurine01.02.20232024
A02BX16irsogladine01.02.20232024
A02BD17vonoprazan and amoxicillin01.02.20232024
A02BC51omeprazole, combinations01.02.20232024

Last updated: 2022-11-25